Single and Multiple Dose Escalation Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAY 3283142 Given as Immediate Release (IR) Tablets in Chinese Healthy Participants in a Randomized, Placebo-controlled, Single-blind, Group-comparison Design
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Nurandociguat (Primary)
- Indications Diabetic retinopathy; Renal failure
- Focus Adverse reactions
- Sponsors Bayer
Most Recent Events
- 24 Sep 2024 Status changed from active, no longer recruiting to completed.
- 23 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 25 Jul 2024 Status changed from not yet recruiting to recruiting.